Drug intelligence / Profile preview

fluorouracil + carmustine + dacarbazine + prednisolone

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy regimen consisting of fluorouracil (antimetabolite), carmustine (alkylating agent), dacarbazine (synthetic purine analog), and prednisolone (corticosteroid). This regimen has been used in the treatment of metastatic breast cancer. Clinical studies showed complete or partial remission in patients with varying levels of prior treatment exposure. The regimen was generally well-tolerated with main side effects including hemopoietic suppression, nausea, vomiting, and alopecia.

Targets

DNATS (Thymidylate synthase)GR (Glucocorticoid receptor)GSR (Glutathione reductase)

Beyond the preview

Go deeper on fluorouracil + carmustine + dacarbazine + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluorouracil + carmustine + dacarbazine + prednisolone.

Explore the full profile